Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Cadi 05 (Primary) ; Cyclophosphamide; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Cadila Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2012 Actual patient number is 134 according to ClinicalTrials.gov.
- 09 Mar 2012 Planned end date changed from 1 Nov 2010 to 1 Jan 2013 as reported by ClinicalTrials.gov.